Essayer OR - Gratuit

“APAC, post-COVID-19, will see an explosion of innovation in digital health”

BioSpectrum Asia

|

August 2020

The ongoing COVID-19 pandemic plaguing countries worldwide has created unprecedented change for the global economy, especially healthcare institutions at the forefront. Hospitals across the world are facing never before seen challenges that have accelerated the development of technological innovations. As we navigate the complexities of the virus and the amount of disruption it has brought about, one thing is certain – COVID-19 will be with us for the foreseeable future. It’s time to focus on this new reality and how we can achieve a sense of normalcy. Dr. Ian Chuang, who is currently the Chief Medical Officer at Elsevier shares his insights on how the healthcare ecosystem can prepare for the ‘new normal’ in a post-COVID-19 world. Edited excerpts;

- Hithaishi C Bhaskar

“APAC, post-COVID-19, will see an explosion of innovation in digital health”

Dr Ian Chuang, Chief Medical Officer, EMEALAAP Health, Elsevier, Kansas City, Missouri Area, USA

How can healthcare ecosystems establish a strategic and resilient pandemic preparedness model?

There are and continue to be many lessons to be learned from this pandemic. Some of the areas are broad and systemic, requiring larger-scale evaluation of the fundamentals of the healthcare system and model of care itself. Ideally, we proceed with any change in a human-centered design thinking approach.

With many uncertainties about the disease, the COVID-19 pandemic has highlighted the importance of accessible and trusted data for frontline clinicians providing care. The pandemic crisis has sped up the delivery and accentuated the weakness in the healthcare system. The healthcare system was not ready when the disease first broke, putting a strain on the entire health system. As healthcare workers were over-taxed and reacting to the evolving crisis, patients were left to figure things out on their own. There was no recipe to fall back. Doctors’ offices were closed, elective surgeries canceled, and patients did not know where to seek care, let alone whether the Emergency Department was safe. The healthcare system was barely keeping up with the demands of COVID-19 related care; definitely, there was a shortfall of how well other care needs were met.

PLUS D'HISTOIRES DE BioSpectrum Asia

BioSpectrum Asia

BioSpectrum Asia

Waters launches charge detection mass spectrometry technology

US-based Waters Corporation has unveiled the Waters Xevo Charge Detection Mass Spectrometer (CDMS), delivering unmatched measurement and characterisation for the broadest range of mega-mass biomolecules central to next-generation therapeutics and structural biology.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

Chulalongkorn University launches Thailand's first master's programme in Nurse Anesthesia

The Faculty of Nursing, Chulalongkorn University, has officially launched the \"Master of Nursing Science Programme in Nurse Anesthesia\" - the first of its kind in Thailand.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

WHO strengthens coordination for NTD programmes and supply chain delivery

The World Health Organization (WHO), together with health ministries, pharmaceutical donours, implementing partners and technical support platforms, is strengthening coordination for neglected tropical disease (NTD) programmes and supply chain delivery, through three major back-to-back meetings in Geneva.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

All-in-one coronavirus vaccines to save millions in future pandemics

A new study reveals that vaccines designed to protect against a wide range of coronaviruses could dramatically reduce deaths and economic disruption and limit the need for lockdowns in the event of another global coronavirus pandemic.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

NTU in Singapore introduces Master of Science course in Chinese Medicine

From 2026, Nanyang Technological University (NTU) in Singapore will start offering a Master of Science in Chinese Medicine to develop highly skilled postgraduates with advanced expertise in both the theoretical foundations and practical applications of Chinese medicine.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

ProSpecBio launches Activin-A recombinant protein for brain injury research

Israel-based ProSpecBio, an evolving biotech company dedicated to providing highly purified proteins to the global research community, has announced the launch of its latest product: CHO cell-derived recombinant Activin-A, now available for immediate delivery worldwide.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

PAHO publishes guide for designing AI instructions in public health

The Pan American Health Organization (PAHO) has launched a new guide providing practical advice on how to create Artificial Intelligence (AI) prompts that generate reliable, relevant, and culturally appropriate content across diverse contexts.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

Prerna launches India's first MicroRNA based blood test for breast cancer screening

Precision RNA Biotech (Prerna), a healthcare startup from Hyderabad, India has announced the launch of Cantel, India's first microRNA-based blood test for breast cancer screening.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

Poly Medicure announces acquisition of Citieffe Group for Rs 324 Cr

India-based medtech firm Poly Medicure has announced signing of a definitive agreement to acquire 100 per cent stake in Medistream SA (Group) consisting of Citieffe SRL and its step-down subsidiaries in USA & Mexico, at an Enterprise Value of Rs 324 crore (EUR 31 million).

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

Sumitomo, Novo Nordisk to co-promote obesity drug Wegovy in Japan

Sumitomo Pharma and Novo Nordisk Pharma have entered into a co-promotion agreement in Japan for Wegovy Subcutaneous Injection, a once-weekly subcutaneous injection formulation of GLP-1 receptor agonist indicated for the treatment of obesity disease.

time to read

1 min

BioSpectrum Asia Nov 2025

Translate

Share

-
+

Change font size